Deals, Partnering

Lundbeck acquires rights to Merck & Co.’s bipolar disorder treatment

Posted on 12 October 2010

Tags: , ,

Lundbeck A/S (Lundbeck) and Merck, known outside the U.S. and Canada as MSD, have announced a worldwide commercialization agreement for Sycrest® (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to Sycrest in all markets outside the United States, China and Japan. More details on the Lundbeck/Merck commercialization agreement (link no longer available)

Print Friendly, PDF & Email

Leave a Reply